Yilmaz, Musa http://orcid.org/0000-0002-4498-4895
Kantarjian, Hagop http://orcid.org/0000-0002-1908-3307
Short, Nicholas J. http://orcid.org/0000-0002-2983-2738
Reville, Patrick http://orcid.org/0000-0001-8433-3360
Konopleva, Marina http://orcid.org/0000-0002-9347-2212
Kadia, Tapan http://orcid.org/0000-0002-9892-9832
DiNardo, Courtney http://orcid.org/0000-0001-9003-0390
Borthakur, Gautam http://orcid.org/0000-0001-7679-6453
Pemmaraju, Naveen http://orcid.org/0000-0002-1670-6513
Maiti, Abhishek
Jabbour, Elias http://orcid.org/0000-0003-4465-6119
Jain, Nitin
Issa, Ghayas http://orcid.org/0000-0002-4339-8683
Takahashi, Koichi http://orcid.org/0000-0002-8027-9659
Sasaki, Koji http://orcid.org/0000-0002-9140-0610
Ohanian, Maro
Pierce, Sherry
Tang, Guillin http://orcid.org/0000-0002-9482-4806
Loghavi, Sanam http://orcid.org/0000-0001-8980-3202
Patel, Keyur http://orcid.org/0000-0001-5081-2427
Wang, Sa A.
Garcia-Manero, Guillermo http://orcid.org/0000-0002-3631-2482
Andreeff, Michael http://orcid.org/0000-0002-1144-1958
Ravandi, Farhad http://orcid.org/0000-0002-7621-377X
Daver, Naval http://orcid.org/0000-0001-7103-373X
Article History
Received: 22 February 2022
Revised: 30 March 2022
Accepted: 7 April 2022
First Online: 2 May 2022
Competing interests
: ND has received research funding from Daiichi Sankyo, Bristol-Myers Squibb, Pfizer, Karyopharm, Sevier, Genentech, Astellas, Sobi, Hanmi, Fate, Gilead, Forty-Seven, Trillium, KAHR, KITE, and ImmunoGen and has served in a consulting or advisory role for Daiichi Sankyo, Bristol-Myers Squibb, Pfizer, Syndax, Astellas, Immunogen, Glycostem, Novartis, Celgene, AbbVie, Arch oncology, KITE, Gilead, Servier, Trillium, Shattuck labs, and Agios. MY received research funding from Pfizer and Daiichi Sankyo. The authors declare no competing interests.